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Advanced Therapy Medicinal Products (ATMPs) which include gene and somatic-cell therapies and 
tissue-engineered medicines, have the potential to transform current care pathways by offering 
durable and potentially curative outcomes. However, they are exceptionally expensive, with prices 
exceeding £1m per patient in some cases. With an expectation that a large number of ATMPs will soon 
gain marketing authorisation (global market is estimated to reach £9bn to £14bn by 2025), healthcare 
payers and providers face a number of challenges to facilitate patient access to this new category of 
medicines. 
 
This viewpoint reflects on the experience of introducing ATMPs into the National Health Service in 
Wales where £1 in every £200 spent on medicines in Wales (2019/20) is expected to be on ATMPs for 
just 20 patients. Evidence to date makes it apparent that decisions regarding clinical and cost-
effectiveness, and the scale of the budget impact of implementing ATMPs creates both financial and 
service risks. Consequently, there are significant policy implications. A critical examination is made of 
the approaches taken for the health technology assessment and appraisal of ATMPs, the methods of 
payment and service impacts of these medicines, and the approach taken to horizon scanning and 




Advanced Therapy Medicinal Products (ATMPs) that aim to repair, replace, regenerate and re-
engineer genes, cells and tissues have the potential to transform current care pathways by offering 
durable and curative outcomes. Interest in the development and use of ATMPs is growing, prompted 
by promising early results with chimeric antigen receptor (CAR) T-cell therapies for refractory or 
relapsed haematological malignancies. 
 
There are currently 10 ATMPs available within the European Union [1] and, with more expected to 
gain market authorisation, concerns have been expressed about the significant cost to healthcare 
payers, including the National Health Service (NHS) in the UK.  There is a risk that ATMPs will either 
not be affordable or other treatments and services may need to be displaced in order to fund them. 
In addition, healthcare services in the UK are not currently configured to accept, adopt and deploy 
these therapies routinely. 
 
This viewpoint reflects on recent experience within the devolved NHS in Wales, where the 
Government has set out its intention for Wales to be at the forefront of the new opportunities that 
ATMPs present [2].  The context in Wales – where it is expected that £1 in every £200 spent on 
medicines in 2019/20 will be on ATMPs for 20 patients – is likely to be reflective of the wider NHS 
across the UK. 
 
Health Technology Assessment and Appraisal 
To date, the majority of ATMPs have been marketed with a narrow license indication and often for 
use in second or subsequent lines of treatment. Often HTA bodies have only phase I and II studies to 
assess their clinical effectiveness, and most studies are multicentre, open-label and lack comparator 
data [3]. In the absence of trial-based comparisons, there is increased reliance on indirect comparisons 
using historical controls, which introduces significant bias. Additional challenges in assessing the 
clinical effectiveness of ATMPs are the lack of long-term outcome data, including health-related 
quality of life and survival, and reliance on endpoints that may not be good surrogates for outcomes 
that matter to patients. 
 
A critical feature of ATMPs is their price. Tisagenlecleucel has a UK list price of £282,000 for a one-
time infusion, Strimvelis® costs £594,000 per patient, and autologous CD34+ cells encoding βA-T87Q-
globin gene (Zynteglo®) for beta thalassaemia costs over £1m (Table 1). Onasemnogene abeparvovec-
xioi (Zolgensma®) for spinal muscular atrophy is poised to enter European markets, with a current US 
price of $2.1m. Consequently, providers are faced with difficult decisions concerning their value for 
money, reimbursement and budget impact implications. 
 
The first wave of ATMPs assessed by the National Institute for Health and Care Excellence (NICE) were 
recommended for use via the cancer drugs fund (CDF) and are mandated in NHS Wales (Table 1). 
Appraisals under the CDF process means that different value judgements have been made in terms of 
evidentiary standards and value for money. The standard incremental costs effectiveness ratio (ICER) 
threshold of £20,000 per quality-adjusted life year (QALY) (up to £30,000 exceptionally) is not followed 
routinely. For many treatments, the ICER is not calculable, and for others, a threshold of £50,000 per 
QALY is more often applied [4]. It is anticipated that some ATMPs with non-cancer indications may be 
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evaluated via the NICE Highly Specialised Technologies route in future, which operates a threshold of 
up to £300,000 per QALY [5]. 
 
Some have commented on the unique features of ATMPs in terms of being more likely to be one-off 
treatments that are designed to be curative [6], and that these may warrant a different analytical 
approach. The application of the standard 3.5% per annum discount rate for benefits, for instance, 
will reduce the net present value of the long-term effects of ATMPs and increase the ICER. Some 
diseases such as haematological malignancies may not present until later in life (> 65 years), and this 
may create a challenge in terms of defining the lifetime benefit a patient may gain from curative 
treatment, and risk an unintended age bias. However, all these challenges are encountered in the 
assessments and appraisals of other health technologies (such as, one-off curative surgery which may 
also be costly but associated with large health benefits). NICE has determined that its standard HTA 
methods and processes for considering the clinical- and cost-effectiveness are appropriate for ATMPs 
[7]. However, the Institute for Clinical and Economic Review in the USA published adaptations to its 
value assessment framework for potential cures and other treatments that qualify as “high-impact, 
single or short-term therapies” [8].  
 
Economic evaluations of ATMPs conducted to date suggest that ICERs are generally high and 
associated with significant uncertainty and potential bias owing to methodological challenges caused 
by the paucity of data on long-term outcomes [9]. 
 
Paying for ATMPs 
Current ATMPs are purchased via standard method of reimbursement with an upfront cost for the 
product irrespective of success or failure of the treatment. Innovative payment methods may need to 
be developed to manage and share risk to facilitate timely patient access while the evidence matures. 
Whilst a simple patient access scheme discount has been negotiated for all the NICE-approved ATMPs 
so far, it may be necessary or desirable to look at different ways of paying. Upfront payments provides 
reimbursement to the manufacturers of the full value of the ATMP, with all the financial risks placed 
on the NHS. Alternatives, such as annual payments over a defined period dependent on continued 
successful response to treatment, and outcomes-based contracting payment schemes are likely to 
feature in the near-future commissioning of ATMPs [10]. 
 
Impact on Service Delivery 
The first wave of ATMPs has provided an opportunity to learn about the practical service delivery 
considerations related to these new technologies including: 
• Logistics – the timing of cell collection, transportation, processing and re-implantation is critical. 
• ATMP production – the harvesting and processing of a patient’s cells for CAR T-cell therapy, for 
instance, is complex and can involve transportation and processing across more than one country. 
• Delivery mechanism – the service delivery pathway is similar to autologous stem cell 
transplantation. The critical phases are patient preparation including any chemotherapy or drug 
treatment or prehab, treatment with the product and aftercare including management of 
complications. 
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• Complications – CAR T-cell therapies can provoke a life threatening cytokine response syndrome 
requiring a period of emergency treatment in an intensive care environment. This creates an 
additional pressure on capacity in this area. 
• Success rates – treatment success rates vary, axicabtagene ciloleucel achieved 1-year complete 
response rates of 40% [11]. A majority of patients will therefore still require standard of care, 
which may include salvage therapies and progression to palliative care. 
• New line versus substitution – the first wave of treatments are a new line of treatment rather than 
substitution, thus providing limited opportunity to release resources and realise savings from 
current services.  
• Centre capacity – there are a limited number of designated centres, but not all are in operation. 
Patient treatments are currently being prioritised by a national (UK) process and being allocated 
to treatment centres.  
 
Scanning the Horizon for New ATMPs 
Horizon scanning aims to support planning and priority-setting by increasing awareness of new and 
emerging health technologies. Developing an accurate financial projection is challenging, and horizon-
scanning activities can provide valuable intelligence on: 
• Different options of how quickly the pipeline of new ATMPs will turn into approvals – the most 
likely scenario is a surge in the next five years, before reaching a steady state. 
• The numbers of patients – this is extremely difficult without an understanding of the specific 
disease groups impacted by new ATMPs.  However, a budget impact model will need to take into 
account that the numbers needing treatment may be greater in the early years as prevalent cases 
are gradually replaced by incident patients. 
• Additional financial risks, including whether the place in therapy of the ATMP will change over 
time – experience of use and strategies to manage safety concerns may increase the likelihood of 
ATMPs being used earlier, even as first line therapy.   
• Payment schemes – it is likely that the pricing structure used by industry will push towards upfront 
costs while benefits are likely to accrue in the long term. 
• The associated NHS costs – the total costs to the service is likely to far exceed the drug acquisition 
costs. The total cost of CAR T-cell therapy, for instance, needs to also consider the costs associated 
with leukapheresis and lymphodepletion therapy, as well as the costs of managing adverse effects, 
which is significant with 44% of patients who received tisagenlecleucel in clinical trials requiring 
stays in the intensive care unit for cytokine release syndrome [12]. Advance knowledge of such 
costs are an important component of horizon scanning. 
 
Long Term Financial Forecasting for NHS Wales 
During 2018-19, NICE published four guidances on ATMPs, with total projected costs to NHS Wales of 
£4.381m in 2019/20, rising to £6.924m in 2020/21. This represents 0.75% and 1.10% of the annual 
revenue budget for specialised services, and 0.48% and 0.70% of the annual NHS Wales medicines 
budget allocated to only 0.00063% of the population. There are currently over 959 companies 
worldwide developing ATMPs, with products being tested in 1052 clinical trials [13]. As many as 70 
ATMPs could become available in the UK by 2024, although not all will progress to gaining marketing 
authorisation [14]. Accurate financial forecasting is therefore essential to plan future services, and to 
make provisions (or savings in other health services) in order to finance new and existing ATMPs. In 
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practice there is greater certainty regarding the 1-year horizon as products are scheduled within the 
NICE ‘forward look’ timetable. Greater uncertainty is inevitable in longer term forecasting, as 
information on available treatments, their clinical indications and costs is very limited.  
 
The results of a rudimentary model of the potential scale of the future (10-year) financial impact of 
ATMPs on the NHS Wales budget are depicted in Figure 1. This considers the cost of the ATMP 
including the cost of manufacturing, transport and supply; and the cost of care, including hospital 
admissions. The model assumes future ATMPs become available at a modest rate of up to 5 new 
products per annum, and include 1 rare disease, 3 cancer and 1 haematological indication. With the 
exception of the rare disease indication (£1m), the costs of new ATMPs are conservatively assumed 
to be 10% lower than existing products. Service costs are also decreased by 25% to reflect the new 
NHS England tariff price of £92,000 [15].  Whilst a tariff price reduces the degree of uncertainty, it is 
not clear whether this will be deliverable in practice or be reflective of actual costs, as it excludes the 
product, intensive care and preparatory treatment costs. The cumulative indicative costs reaches over 
£150m by year 10, and this has policy implications for the Welsh Government in terms of priorities 
and strategic transformation resources. 
 
Conclusions and recommendations 
The introduction of ATMPs undoubtedly creates new opportunities for providing new curative 
treatments and potentially wider benefits to the economy [16]. The Advanced Therapy Treatment 
Centres, which aim to provide the necessary commercial and NHS infrastructure required to facilitate 
the delivery of ATMPs to patients, represent one opportunity for the UK to be at the forefront of ATMP 
research and innovation. 
 
However, these will depend critically on NHS resources, including workforce capacity for successful 
translation to clinical practice and improved patient outcomes. The scale of the financial challenge 
potentially presents a major financial risk over the next five to ten years.  Consequently, there are 
significant policy issues arising, including the level at which payers of healthcare are willing to fund 
ATMPs, the methods of evaluation, the need to challenge how these treatments are priced by the 
pharmaceutical industry and what prioritisation trade-offs the NHS is willing to make in order to 
implement. There are significant uncertainties in terms of the pace of new approvals and the numbers 
of patients that may benefit from treatment.  The current pipeline is concentrated on rarer diseases 
but may broaden over time with further financial and service risks associated with this. There is a need 
to develop alternative methods of managing costs, such as annuity or amortisation of payments over 
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Therapy (trade name)a Indication Total treatment 
cost per patientb 
Estimated number 




HST7 Autologous CD34+ cells transduced with 
retroviral vector that encodes for the 
human ADA cDNA sequence (Strimvelis®) 
Adenosine deaminase deficiency–severe 
combined immunodeficiency 
£594,000 1 every 5 years £237,600 
TA554 Tisagenlecleucel (Kymriah®) Relapsed or refractory B-cell acute 
lymphoblastic leukaemia in people aged up 
to 25 years 
£420,000 2 £840,000 
TA567 Tisagenlecleucel (Kymriah®) Relapsed or refractory diffuse large B-cell 
lymphoma after 2 or more systemic 
therapies 
£420,000 13 £5,460,000 
TA559 Axicabtagene ciloleucel (Yescarta®) Diffuse large B-cell lymphoma and primary 
mediastinal large B-cell lymphoma after 2 or 
more systemic therapies 
£420,000 13 £5,460,000 




Thymidine kinase cell therapy 
(Zalmoxis®) 
Adjunctive treatment in haploidentical 
haematopoietic stem cell transplantation of 





HST11 Voretigene neparvovec (Luxturna®) Inherited retinal dystrophies £306,705 per eye 4 £1,226,820 
TA467 Ex vivo expanded autologous human 
corneal epithelial cells containing stem 
cells (Holoclar®) 
Limbal stem cell deficiency after eye burns £80,000 per eye 510 £800,000 
TA508 Chondrosphere (Spherox®) Symptomatic articular cartilage defects of 
the knee 
£10,000 20 £200,000 
TA556e Darvadstrocel (Alofisel®) Complex perianal fistulas in Crohn’s disease £54,000 n/a n/a 
ID968f Autologous CD34+ cells encoding βA-
T87Q-globin gene (Zynteglo®) 
Beta thalassaemia in patients 12 years and 
older who require regular blood 
transfusions 
£1,120,000 n/a n/a 
a ATMPs that have been withdrawn from use in the EU include: ChondroCelect® (characterised viable autologous cartilage cells expanded ex vivo expressing specific marker 
proteins), Glybera® (alipogene tiparvovec), Maci® (matrix-applied characterised autologous cultured chondrocytes) and Provenge® (sipuleucel-T)  
b Includes the cost of the therapy and, for CAR T-cell therapies, all other associated treatment costs (for example ICU provision, managing treatment side effects) 
c Put into context, the population of Wales (2019) is 3,184,000; the total NHS costs of medicines, including primary care prescribing (2018/19) was £911.3m; the cost of 
hospital-prescribed medicines (2018/19), excluding cancer medicine was £348.2m; and the cost of hospital-prescribed cancer medicines (2018/19) was £108.1m 
d Not approved for use in NHS Wales 
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e Not recommended for use in NHS Wales 
f Currently being appraised by NICE. Decision expected June 2020 
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Legend: Projected total costs, patient numbers and new clinical indications for ATMP (upper panel); 
average cost per patient and total number of patients (lower panel). 
 
